NeuroSense Therapeutics (NASDAQ:NRSN) Earns Buy Rating from D. Boral Capital

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock.

A number of other equities research analysts also recently issued reports on NRSN. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Finally, Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Price Performance

NASDAQ NRSN opened at $0.77 on Wednesday. The firm’s 50-day moving average is $0.89 and its two-hundred day moving average is $1.01. NeuroSense Therapeutics has a 12 month low of $0.63 and a 12 month high of $2.60.

Institutional Trading of NeuroSense Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Yorkville Advisors Global LP acquired a new stake in shares of NeuroSense Therapeutics during the fourth quarter worth about $77,000. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the third quarter valued at approximately $26,000. Squarepoint Ops LLC grew its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the second quarter valued at approximately $54,000. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.